Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A, Vannucchi AM, Barbui T.
Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25.
Essential thrombocythemia: challenges in clinical practice and future prospects.
Godfrey AL, Green AC, Harrison CN.
Blood. 2023 Apr 20;141(16):1943-1953. doi: 10.1182/blood.2022017625.
Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?
Spivak JL.
Leukemia. 2021 Jul;35(7):1890-1893. doi: 10.1038/s41375-021-01254-w. Epub 2021 Apr 28.
Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
Tefferi A, Szuber N, Pardanani A, Hanson CA, Vannucchi AM, Barbui T, Gangat N.
Am J Hematol. 2021 Jun 1;96(6):E182-E184. doi: 10.1002/ajh.26137. Epub 2021 Mar 11.
Essential thrombocytosis attributed to JAK2-T875N germline mutation.
Yoshimitsu M, Hachiman M, Uchida Y, Arima N, Arai A, Kamada Y, Shide K, Ito M, Shimoda K, Ishitsuka K.
Int J Hematol. 2019 Nov;110(5):584-590. doi: 10.1007/s12185-019-02725-8. Epub 2019 Aug 19.
Haemorrhagic thrombocytosis revisited?
Lofaro T, Harrison CN.
Eur J Haematol. 2015 Jan;94(1):1. doi: 10.1111/ejh.12418.
Thrombocytosis.
Schafer AI.
JAMA. 2015 Sep 15;314(11):1171-2. doi: 10.1001/jama.2015.8515.
Long-term management of thrombocytosis in essential thrombocythaemia.
Birgegård G.
Ann Hematol. 2009 Jan;88(1):1-10. doi: 10.1007/s00277-008-0531-7. Epub 2008 Jul 16.
Thrombocytosis.
Schafer AI.
N Engl J Med. 2004 Mar 18;350(12):1211-9. doi: 10.1056/NEJMra035363.
Essential thrombocythaemia.
Harrison CN, Green AR.
Best Pract Res Clin Haematol. 2006;19(3):439-53. doi: 10.1016/j.beha.2005.07.004.
